Innate Pharma (IPHA) Stock Overview
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IPHA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Innate Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.77 |
| 52 Week High | €2.63 |
| 52 Week Low | €1.60 |
| Beta | 0.59 |
| 1 Month Change | -6.84% |
| 3 Month Change | -12.81% |
| 1 Year Change | -3.28% |
| 3 Year Change | -52.03% |
| 5 Year Change | -62.34% |
| Change since IPO | -71.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| IPHA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.1% | 0.7% | 1.0% |
| 1Y | -3.3% | 23.7% | 17.2% |
Return vs Industry: IPHA underperformed the US Biotechs industry which returned 23.7% over the past year.
Return vs Market: IPHA underperformed the US Market which returned 17.2% over the past year.
Price Volatility
| IPHA volatility | |
|---|---|
| IPHA Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IPHA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IPHA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 174 | Jonathan Dickinson | www.innate-pharma.com |
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
Innate Pharma S.A. Fundamentals Summary
| IPHA fundamental statistics | |
|---|---|
| Market cap | US$167.76m |
| Earnings (TTM) | -US$53.79m |
| Revenue (TTM) | US$14.76m |
Is IPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPHA income statement (TTM) | |
|---|---|
| Revenue | €12.64m |
| Cost of Revenue | €43.42m |
| Gross Profit | -€30.79m |
| Other Expenses | €15.26m |
| Earnings | -€46.05m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Mar 26, 2026
| Earnings per share (EPS) | -0.50 |
| Gross Margin | -243.65% |
| Net Profit Margin | -364.44% |
| Debt/Equity Ratio | 513.5% |
How did IPHA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/07 01:49 |
| End of Day Share Price | 2026/01/07 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innate Pharma S.A. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Yigal Nochomovitz | Citigroup Inc |
| Michael Thomas Cooper | Edison Investment Research |